Nutlin-3

目录号:S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。

规格 价格 库存 购买数量  
RMB 1515.15 现货
RMB 900.36 现货
RMB 1407.13 现货
RMB 3026.07 现货
RMB 7939.67 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。
靶点
Mdm2 [5]
(Cell-free assay)
180 nM
体外研究

Nutlin-3有效抑制MDM2-p53相互作用,IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞,如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性,IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时,显著诱导caspase依赖的细胞凋亡,凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力,IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力,而3 μM Nutlin-3 处理SJSA-1细胞后,细胞则无活力。[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化,在特定DNA结合序列没有区别,且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比, 使p53靶点基因转活,说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。[2] 虽然与MDM2相比,Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1),能抑制MDMX–p53相互作用,且诱导 p53通路,IC50为0.7 μM。[3] 30 μM Nutlin-3作用于无野生型p53的细胞,也扰乱内源性p73-HDM2 相互作用,且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制,和诱导凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M3P5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq1xsDPxE1? NIHIPJQ1QMLiaB?= MkH1Zoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ MnfuNlY{PTB3NkW=
NP69 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3R|NZUUN3ME2zNU43QcLzMj61OEDPxE1? MUWyOlI2OjV5NR?=
NP460 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5ZlRkUUN3ME2yNk45PcLzMT6xPEDPxE1? M4DBUVI3OjV{NUe1
C666-1 M3T1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfOblVKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? MUmyOlI2OjV5NR?=
C666-1 Mn7FR4VtdCCYaXHibYxqfHliQYPzZZk> NH70V3cyOCEEtV2= M{S3bFQ5KGh? MV7EUXNQ MkTnd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw Ml\NNlYzPTJ3N{W=
C666-1  MkTuSpVv[3Srb36gRZN{[Xl? NXS4PGtjOTBiwsXN MVKyOEBp MVrEUXNQ NUjuSnJH[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ MkTNNlYzPTJ3N{W=
C666-1 MmrFRZBweHSxc3nzJGF{e2G7 MmLuNVAhyrWP MYS0PE84OiCq NH;wXYdFVVOR NEKwSXl{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NXT1SZNTOjZ{NUK1O|U>
A549 M2qydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rDfVI1KGh? MX3JR|UxRTF5Lk[4JOKyKDRwNUKg{txO M1Luc|I3OTJ3MkOw
A549-NTC NXHr[otUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLONlQhcA>? M{nNRmlEPTB;MUmuOFIhyrFiMT65OkDPxE1? NETmU48zPjF{NUKzNC=>
A549-920 NFLjPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TwNlI1KGh? NGHMS5pKSzVyPUOzMlg2KMLzIESuPFQh|ryP NVq1fGJ[OjZzMkWyN|A>
CRL-5908 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLuNlQhcA>? MnXyTWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? MVWyOlEzPTJ|MB?=
L6 NXfJVoNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNOKh|ryPwrC= MWWyOE81QC95MjDo M4rDNGROW09? MnXtbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M3TVVVI2QDdzN{m0
C2C12 NF3qco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNOKh|ryPwrC= M3TSZ|I1NzR6L{eyJIg> Ml;VSG1UVw>? MVTpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> MkLYNlU5PzF5OUS=
MCF-7  M3XT[WZ2dmO2aX;uJGF{e2G7 MlP1NVDDqM7:TR?= MlrYSG1UVw>? M3u1UolvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NFjxNFAzPTdyMkewNy=>
DU4475  MlzZSpVv[3Srb36gRZN{[Xl? NWfkb2NvPS9zMD:yNEDPxE1? MX:yOOKhcA>? MXrkc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5 MomyNlU2PDdzN{S=
SMMC-7721 MoDBSpVv[3Srb36gRZN{[Xl? M4TR[VExKM7:TR?= MVG0PEBp NHzwPJJFVVOR MmDyZ4F2e2W|IFTORUBFW0JiZHHtZYdm MkjENlU2PDR|NkG=
SMMC-7721 NGDQfVFHfW6ldHnvckBCe3OjeR?= MWOxNEDPxE1? NX\xRnY1PDhiaB?= MVjEUXNQ NGDzOZNqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh NX\JeZU{OjV3NESzOlE>
SMMC-7721 MVTGeY5kfGmxbjDBd5NigQ>? MYqxNEDPxE1? NF;XTJc1QCCq MX;EUXNQ MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B NIOzVIIzPTV2NEO2NS=>
SMMC-7721 Mn:xSpVv[3Srb36gRZN{[Xl? M{n2[lExKM7:TR?= M2nydFM3KGh? M4\jXWROW09? MXfjZZV{\XNidHjlJIVkfG:yaXOg[ZhxemW|c3nvckBw\iCLRlmxOi=> NYHISIJkOjV3NESzOlE>
MCF-7 Ml3lSpVv[3Srb36gRZN{[Xl? MmW2NVDDqM7:TR?= Mn7BNE0zPCCq M4rzTolv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= NYT5UJh3OjV2OEKzO|M>
OVCAR10 NGS1O2JHfW6ldHnvckBCe3OjeR?= NXzORYluOTEEoN88US=> MYeyNYjDqA>? NVfGR3Z2TE2VTx?= NXnaeWlYcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NYrySGtJOjV2Mk[1OFg>
NCI-H23 NFTTV5RHfW6ldHnvckBCe3OjeR?= M{PZ[FExyqEQvF2= NFvoWIEzOWkEoB?= MkXrSG1UVw>? MonwbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> M2jpZVI2PDJ4NUS4
A2780 MlXZSpVv[3Srb36gRZN{[Xl? MXixNOKh|ryP NGHGR2IzOWkEoB?= M3Xwd2ROW09? MUfpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MY[yOVQzPjV2OB?=
NCI-H23 M3HEeGZ2dmO2aX;uJGF{e2G7 MW[xNOKh|ryP NFjaem8zOWkEoB?= NV\mb5RITE2VTx?= NWTSOVNp\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> NV3qPGcxOjV2Mk[1OFg>
A2780 NX3HZ242TnWwY4Tpc44hSXO|YYm= NIfoSpEyOMLizszN M{XMSlIycMLi Mn;WSG1UVw>? M1zac4Rm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NYfJcG11OjV2Mk[1OFg>
HCT116  NXLwS21HTnWwY4Tpc44hSXO|YYm= MlS4NVAhyrWP NHLyfGgzPCCq MlfHZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 NGKydVEzPTN6MEC1OS=>
MCF-10CA1a M2LqOWZ2dmO2aX;uJGF{e2G7 NYHZSlQ2OTEEoN88US=> NUjCS2J[PDhiaB?= NFjLb|hFVVOR NVradW5scW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= MUeyOVI2Pzd{OR?=
MCF-10A1  M3nqfmZ2dmO2aX;uJGF{e2G7 NXTXOXhwOTEEoN88US=> M2rZNVI1NzR6IHi= M4Xuc2ROW09? MnXjbY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh NVvjWGkxOjV{NUe3Nlk>
MCF-10CA1a MnjMSpVv[3Srb36gRZN{[Xl? M2TNV|ExyqEQvF2= NUDC[YlvOjRiaB?= MnrBSG1UVw>? NXPLbIZs\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= MknPNlUzPTd5Mkm=
MCF-10CA1a MYLGeY5kfGmxbjDBd5NigQ>? NXfLTJlTOTEEoN88US=> NIHHfIEzPCCq NVfIdYN[TE2VTx?= NYnKZ4FvcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NWT6ZWU2OjV{NUe3Nlk>
SK-BR-7 NVzFenRoTnWwY4Tpc44hSXO|YYm= M4CzfVExyqEQvF2= MUGyOEBp MnTRSG1UVw>? Mk[2bY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NHzGbmIzPTJ3N{eyPS=>
SUM102PT NV7M[HRKTnWwY4Tpc44hSXO|YYm= M2P5WVExyqEQvF2= NVr1NJhXOjRiaB?= MkniSG1UVw>? MnHtbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NHvHcHczPTJ3N{eyPS=>
RAW 264.7 NWHWdVY3TnWwY4Tpc44hSXO|YYm= NXjHWlRxOTEEoN88US=> MUGzNEBucW5? MWPwdoV3\W62czD0bIUheDV|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO= MVyyOVE4OjV2Nx?=
RAW 264.7 M{\YSmZ2dmO2aX;uJGF{e2G7 MlLPNVDDqM7:TR?= NUfQfolmOzBibXnu M2TOcJJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= NVvqUIJjOjVzN{K1OFc>
RAW 264.7 MXHGeY5kfGmxbjDBd5NigQ>? M4XvWVExyqEQvF2= NX7zVlN5OzBibXnu NXvXc5FrcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh NV7COIE5OjVzN{K1OFc>
MCF7  MnnRR4VtdCCYaXHibYxqfHliQYPzZZk> MU[yMlUhyrWP NXrhdYg3PSCm M1L2OWROW09? Mn[1d4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= NYi1PFg1OjVyOEW5NFI>
MCF7  NUXHSFR7TnWwY4Tpc44hSXO|YYm= MYiyMlUhyrWP MkDFOFghcA>? M1vJTmROW09? NHHp[lRl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? NUDZboxIOjVyOEW5NFI>
ACHN M3fRU2NmdGxiVnnhZoltcXS7IFHzd4F6 M1rzRlAvPS1zMDFOwG0> M4DSSlAuPiCm Mn7KSG1UVw>? Mn;nbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX\RcXdCOjVyNke3PFc>
Caki-2 NH;5SHZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmTVNE42NTFyIN88US=> MWWwMVYh\A>? NXLsU2VCTE2VTx?= MV3pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUXCR3JTOjVyNke3PFc>
A498 NYfLdGU1S2WubDDWbYFjcWyrdImgRZN{[Xl? NXjOb3R4OC53LUGwJO69VQ>? NXXrSYJEOC14IHS= NFnkSWFFVVOR MVPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkPmNlUxPjd5OEe=
115 MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWLHe2hHOC53LUGwJO69VQ>? MonkNE03KGR? NHTFN49FVVOR M3faNYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\wNlUxPjd5OEe=
117 MofwR4VtdCCYaXHibYxqfHliQYPzZZk> MVuwMlUuOTBizszN MlLvNE03KGR? NYfyfpV2TE2VTx?= MULpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4\a[lI2ODZ5N{i3
ACHN NH;tNItHfW6ldHnvckBCe3OjeR?= NWTCR|QyOC53L{GvOUDPxE1? NIfMT2I1QCCq NF;ycVhFVVOR NYXkRoF[dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MUmyOVA3Pzd6Nx?=
Caki-2 NVH3UXBDTnWwY4Tpc44hSXO|YYm= NH;QTVMxNjVxMT:1JO69VQ>? M2DYe|Q5KGh? M1\LW2ROW09? NEXQeYlt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MWqyOVA3Pzd6Nx?=
A498 M4XYXWZ2dmO2aX;uJGF{e2G7 MXqwMlUwOS93IN88US=> MlLhOFghcA>? Ml\tSG1UVw>? MUHs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MWSyOVA3Pzd6Nx?=
115 MYXGeY5kfGmxbjDBd5NigQ>? MmOzNE42NzFxNTFOwG0> Mlm0OFghcA>? MYLEUXNQ M2PROYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NF\3TlIzPTB4N{e4Oy=>
ACHN NEDMUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXPOUDPxE1? NIP6VGs1QCCq MX;EUXNQ M3;PbYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MVqyOVA3Pzd6Nx?=
Caki-2 M2XQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTIdpM2KM7:TR?= NX3EZ5JOPDhiaB?= NEPv[YpFVVOR Mn;LbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MV:yOVA3Pzd6Nx?=
A498 NWrMW2Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPUNYw2KM7:TR?= MmLkOFghcA>? M2PDNWROW09? M2LqbIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MXmyOVA3Pzd6Nx?=
115 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nVUlUh|ryP Ml;0OFghcA>? M{nyc2ROW09? NH\UN|FqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MUmyOVA3Pzd6Nx?=
ACHN MnS1SpVv[3Srb36gRZN{[Xl? NW[zNlVUPSEQvF2= NU\0bYZ3PDhiaB?= NYDlelY2TE2VTx?= NWG2PHZlcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NVy5[2pnOjVyNke3PFc>
Caki-2 NEfl[mNHfW6ldHnvckBCe3OjeR?= MYe1JO69VQ>? NW\QZVhzPDhiaB?= MXLEUXNQ NV\QT4FCcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M{fHOFI2ODZ5N{i3
A498 NHPMRoNHfW6ldHnvckBCe3OjeR?= M3nQOVUh|ryP NHHxV3k1QCCq MWXEUXNQ Mn7ZbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= MmfZNlUxPjd5OEe=
115 MkLDSpVv[3Srb36gRZN{[Xl? M1vROFUh|ryP M1HP[lQ5KGh? M4\iTmROW09? MWjpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MUeyOVA3Pzd6Nx?=
MOLM-13 NFjUZWtHfW6ldHnvckBCe3OjeR?= NH\uTFU3yqEQvF2= MUKwMVghcA>? Mlv2SG1UVw>? NEmwVItqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwOVMtKE2GTUKsJJAzOSCjbnSgZYNmfHmuYYTl[EBxPTN? NIXzco4zPDh6NUC4Ni=>
MOLM-13 M3fKPWZ2dmO2aX;uJGF{e2G7 M3HOT|bDqM7:TR?= NX3GSWw5PiCq M17oSmROW09? M4fCXYVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= NWnYSlVzOjR6OEWwPFI>
HepG2 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Udo44OiCq MoP4SG1UVw>? NVXVboxJUUN3ME2zOU45PiEEsTCyMlkh|ryP M1L3ZlI1QDh2OEC5
HepG2/As Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7sflFJPzJiaB?= NF7XUVFFVVOR MVrJR|UxRTZ6LkGzJOKyKDlwNjFOwG0> MnPsNlQ5QDR6MEm=
SMMC7721 M1W4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDxSI9uPzJiaB?= M{fwTWROW09? NELPeHFKSzVyPUOxMlI5KMLzIESuNkDPxE1? MWWyOFg5PDhyOR?=
SMMC7721/Ac MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGV4U2PzJiaB?= NFW5XmFFVVOR NHLKSItKSzVyPUW1MlIyKMLzIEWuNFMh|ryP NUfUe2FROjR6OES4NFk>
Huh-7 NUjRboNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\tZYc4OiCq M2DvdWROW09? Mo\pTWM2OD1|Mz65OkDDuSB|Lkmg{txO MVOyOFg5PDhyOR?=
Hep3B Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW2PYw4OiCq NYm1O3JCTE2VTx?= MkTmTWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? MkfsNlQ5QDR6MEm=
HepG2 MlSxRZBweHSxc3nzJGF{e2G7 NInadWlqdmS3Y3XzJIFxd3C2b4Ppdy=> NVfGOXhkOjR6OES4NFk>
SMMC7721 NHLIOlFCeG:ydH;zbZMhSXO|YYm= MWnpcoR2[2W|IHHwc5B1d3Orcx?= NEfsSVMzPDh6NEiwPS=>
Huh-7 M3zzZWFxd3C2b4Ppd{BCe3OjeR?= MkDObY5lfWOnczDhdI9xfG:|aYO= M33u[VI1QDh2OEC5
Hep3B MVvBdI9xfG:|aYOgRZN{[Xl? MYDpcoR2[2W|IHHwc5B1d3Orcx?= NEHuVJQzPDh6NEiwPS=>
U2OS  MnW0SpVv[3Srb36gRZN{[Xl? MmXCNlAh|ryP MWKyOEBp NFuwNZBqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX M{P6V|I1QDZ5MkW5
AML2 MnnkRZBweHSxc3nzJGF{e2G7 MX2yM|ExKM7:TR?= NHPOeW0zPC92ODDo Mn2ybY5lfWOnczDhdI9xfG:|aYO= NHfIT4EzPDZ3OUe0PS=>
MOML13 MoL3RZBweHSxc3nzJGF{e2G7 NV\6cmlDOi9zMDFOwG0> MoXqNlQwPDhiaB?= MlribY5lfWOnczDhdI9xfG:|aYO= MVSyOFY2QTd2OR?=
AML2 M2TMfWZ2dmO2aX;uJGF{e2G7 NHi5[WsyOM7:TR?= MmjmNk81KGh? NX[1[4M{cW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> MYSyOFY2QTd2OR?=
AML3 Mm\sSpVv[3Srb36gRZN{[Xl? MlXUNVDPxE1? NFPyd2UzNzRiaB?= NH;KOmpqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NHn4XGozPDZ3OUe0PS=>
MOML13 NY\v[3dnTnWwY4Tpc44hSXO|YYm= MnP1NVDPxE1? NGmxW2MzNzRiaB?= M{T1N4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MXyyOFY2QTd2OR?=
BeWo NIf0clhHfW6ldHnvckBCe3OjeR?= NVK4TY1YOzBiwsXN NF2zcm8zPCCq M{O4T4lv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> NXvXSGpTOjR2OUixOVQ>
BeWo MWnBdI9xfG:|aYOgRZN{[Xl? NVeyd4JFOzBiwsXN NXfvWJpSOjRiaB?= M{n5bolv[3KnYYPld{BieG:ydH;zbZM> M4LySVI1PDl6MUW0
OCI NI[0SXpHfW6ldHnvckBCe3OjeR?= M{nCbFExKM7:TR?= NU\tSYJvOjRiaB?= NVLqWY51fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NYfLbIpCOjR2N{O1OlI>
MOLM NIX3cJhHfW6ldHnvckBCe3OjeR?= Mkf1NVAh|ryP Mk\4NlQhcA>? MXf1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? M3SyW|I1PDd|NU[y
U2OS  MUPGeY5kfGmxbjDBd5NigQ>? M4HlXlIxKM7:TR?= MnfNNlQhcA>? NITvNXNqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NVTlXmtyOjR|Nk[wNFc>
RKO M2DSZ2Z2dmO2aX;uJGF{e2G7 M3fzc|IxKM7:TR?= NGqwXYczPCCq MmjFbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? MV6yOFM3PjByNx?=
U2OS  MUfGeY5kfGmxbjDBd5NigQ>? NV3iW|Z2OjBizszN M4XkUFI1KGh? NV3yUY1rcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> NX\vd5c6OjR|Nk[wNFc>
RKO M{LodGZ2dmO2aX;uJGF{e2G7 MknkNlAh|ryP NFHnUWozPCCq NUfJcHNbcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MYWyOFM3PjByNx?=
SMMC-7721  NYTQenJtS2WubDDWbYFjcWyrdImgRZN{[Xl? NWrFXWgxOS5{NT2yNEDPxE1? M1\wU|I1NzR6L{eyJIg> MUfEUXNQ M2qwSYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NGPSS3EzPDJ6NkOxNi=>
HuH-7 MljuR4VtdCCYaXHibYxqfHliQYPzZZk> M2PFOlEvOjVvMkCg{txO MX6yOE81QC95MjDo NV;mW3NHTE2VTx?= NVzOOI9vcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MXeyOFI5PjNzMh?=
SMMC-7721  NU\EcHFESXCxcITvd4l{KEG|c3H5 NIjPdYgzOCEQvF2= NXLE[4VQPDhiaB?= MVTEUXNQ NHTYc2xqdmS3Y3XzJIFxd3C2b4Ppdy=> NILPS|gzPDJ6NkOxNi=>
HuH-7 MW\BdI9xfG:|aYOgRZN{[Xl? NXzYN5pvOjBizszN M3vHSVQ5KGh? M3\QO2ROW09? NITJPI9qdmS3Y3XzJIFxd3C2b4Ppdy=> Mkj1NlQzQDZ|MUK=
SMMC-7721  Mo[1SpVv[3Srb36gRZN{[Xl? MoXpNVAh|ryP MnLmN|YhcA>? MWXEUXNQ NGT3PVJld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NVLCT29ZOjR{OE[zNVI>
HuH-7 M{f1NWZ2dmO2aX;uJGF{e2G7 MVSxNEDPxE1? NF3qd|M{PiCq M3jDfmROW09? MnSw[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> NUn2[WZqOjR{OE[zNVI>
AT2 M2TISGZ2dmO2aX;uJGF{e2G7 MkCyOU8yOCEQvF2= MUjs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? M4rIfFI1OjRyMkCz
REH MYPGeY5kfGmxbjDBd5NigQ>? NYnYelBFPS9zMDFOwG0> NXTUXJFbdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MlnxNlQzPDB{MEO=
UoCB6 M{nES2Z2dmO2aX;uJGF{e2G7 MmPYOU8yOCEQvF2= Ml;VcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? M{fiUFI1OjRyMkCz
AT2 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXiwMVI2KM7:TR?= NH\OSY5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3O4dlI1OjRyMkCz
REH NHOxRXZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYqwMVI2KM7:TR?= MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NIGwbWkzPDJ2MEKwNy=>
UoCB6 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUHre4htOC1{NTFOwG0> MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M4TadlI1OjRyMkCz
A2780 M1LlUmZ2dmO2aX;uJGF{e2G7 MlXzOU8yOC9{MDFOwG0> NInmfnEzPCCq M3nzWpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NWXMTHM1OjRzM{[xOFc>
H460 NELwdYdHfW6ldHnvckBCe3OjeR?= NHm4dJk2NzFyL{KwJO69VQ>? NV22RZdZOjRiaB?= MXj1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? Mmf2NlQyOzZzNEe=
Lovo  M360XWZ2dmO2aX;uJGF{e2G7 Mn;aOU8yOC9{MDFOwG0> NILE[VczPCCq MUP1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M{\HcVI1OTN4MUS3
A2780 NFjxWXRCeG:ydH;zbZMhSXO|YYm= Mnv5OU8yOC9{MDFOwG0> MoP2NlQhcA>? NFfNSIJmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M13nSFI1OTN4MUS3
H460 NVO5XlcxSXCxcITvd4l{KEG|c3H5 MVK1M|ExNzJyIN88US=> NE\WTYYzPCCq NFfBbndmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NUm3[Id1OjRzM{[xOFc>
Lovo  MV3BdI9xfG:|aYOgRZN{[Xl? NUTNbGdGPS9zMD:yNEDPxE1? M3W5fFI1KGh? NXTw[3Vp\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MUWyOFE{PjF2Nx?=

... Click to View More Cell Line Experimental Data

体内研究 Nutlin-3 按200 mg/kg 剂量口服处理,每天两次,持续3周,显著抑制SJAS-1移植瘤生长,抑制达90%, 而Doxorubicin抑制81%肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Biacore 研究:

在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5,用于固定 PentaHis抗体,为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm2)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO,浓度为10 mM,然后进一步稀释,在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25oC下进行实验。在Nutlin-3存在时,计算MDM2-p53结合情况,作为结合百分数, 使用Microsoft Excel计算IC50。
细胞实验:

[1]

+ 展开
  • Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435
  • Concentrations: 溶于DMSO,终浓度为~ 30 μM
  • Incubation Time: 8, 24, 和 48 小时
  • Method:

    使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。 通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法(TUNEL)染色,使用流式细胞仪和荧光显微镜测定细胞凋亡。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠
  • Formulation: 在 2% Klucel, 0.5% Tween-80配制中配制
  • Dosages: 200 mg/kg
  • Administration: 口服处理,每天两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.5
化学式

C30H30Cl2N4O4

CAS号 890090-75-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3 | Nutlin-3供应商 | 采购Nutlin-3 | Nutlin-3价格 | Nutlin-3生产 | 订购Nutlin-3 | Nutlin-3代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID